Trial · NCT01610414
Results by group186
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 186
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects With Confirmed Herpes Zoster (HZ) Episode | GSK1437173A Group | 49 | Participants | ||
| Number of Subjects With Confirmed Herpes Zoster (HZ) Episode | Placebo Group | 135 | Participants | ||
| Duration of 'Worst' HZ-associated Pain | GSK1437173A Group | 892.0 | T (day) | ||
| Duration of 'Worst' HZ-associated Pain | Placebo Group | 6275.0 | T (day) | ||
| Number of Subjects With Confirmed HZ-associated Complications | GSK1437173A Group | 3 | Participants | ||
| Number of Subjects With Confirmed HZ-associated Complications | Placebo Group | 13 | Participants | ||
| Number of Subjects With Postherpetic Neuralgia (PHN) | GSK1437173A Group | 1 | Participants | ||
| Number of Subjects With Postherpetic Neuralgia (PHN) | Placebo Group | 9 | Participants | ||
| Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects | GSK1437173A Group | Anti-gE, Month 0 | 762.8 | 95% Confidence Interval 568.6 to 1023.5 | mIU/mL |
| Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects | Placebo Group | Anti-gE, Month 0 | 555.0 | 95% Confidence Interval 404.3 to 761.8 | mIU/mL |
| Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects | GSK1437173A Group | Anti-gE, Month 1 | 1844.2 | 95% Confidence Interval 1282.2 to 2652.4 | mIU/mL |
| Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects | Placebo Group | Anti-gE, Month 1 | 556.6 | 95% Confidence Interval 407.3 to 760.6 | mIU/mL |
| Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects | GSK1437173A Group | Anti-gE, Month 2 | 12753.2 | 95% Confidence Interval 7973.0 to 20399.4 | mIU/mL |
| Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects | Placebo Group | Anti-gE, Month 2 | 443.8 | 95% Confidence Interval 330.8 to 595.4 | mIU/mL |
| Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects | GSK1437173A Group | Anti-gE, Month 13 | 3183.8 | 95% Confidence Interval 1869.8 to 5421.2 | mIU/mL |
| Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects | Placebo Group | Anti-gE, Month 13 | 503.6 | 95% Confidence Interval 307.8 to 824.1 | mIU/mL |
| Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects | GSK1437173A Group | Anti-gE, Month 25 | 2819.0 | 95% Confidence Interval 1387.1 to 5729.1 | mIU/mL |
| Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects | Placebo Group | Anti-gE, Month 25 | 527.0 | 95% Confidence Interval 274.3 to 1012.6 | mIU/mL |
| Number of Subjects With Any and Grade 3 Solicited Local Symptoms | GSK1437173A Group | Any Pain, Dose 1 | 688 | Participants | |
| Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Placebo Group | Any Pain, Dose 1 | 56 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01610414/results